Paul Tudor Jones Esperion Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 43,214 shares of ESPR stock, worth $124,024. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,214

Holding current value

$124,024

% of portfolio

0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $87,292 - $130,506	43,214 New	43,214 $115,000
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $59,347 - $87,042	-49,456 Reduced 40.54%	72,525 $100,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $54,066 - $270,333	37,032 Added 43.59%	121,981 $194,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $68,740 - $114,792	13,505 Added 18.9%	84,949 $529,000
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $139,231 - $207,697	25,547 Added 55.66%	71,444 $479,000

Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $127,010 - $177,602	-26,627 Reduced 36.71%	45,897 $292,000
Q1 2022 May 16, 2022	BUY	$3.34 - $5.56 $561 - $934	168 Added 0.23%	72,524 $337,000
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $8,585 - $21,277	1,785 Added 2.53%	72,356 $362,000
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $467,627 - $881,234	41,237 Added 140.58%	70,571 $850,000
Q1 2021 May 17, 2021	SELL	$25.12 - $36.89 $237,283 - $348,462	-9,446 Reduced 24.36%	29,334 $823,000
Q4 2020 Feb 16, 2021	BUY	$24.2 - $35.76 $711,988 - $1.05 Million	29,421 Added 314.36%	38,780 $1.01 Million
Q3 2020 Nov 16, 2020	BUY	$31.18 - $52.71 $291,813 - $493,312	9,359 New	9,359 $348,000
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $340,908 - $470,071	-9,890 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $190,354 - $248,410	4,747 Added 92.3%	9,890 $460,000
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $221,848 - $296,295	-5,531 Reduced 51.82%	5,143 $206,000
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $394,831 - $630,940	10,674 New	10,674 $491,000
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $1.87 Million - $2.9 Million	-42,954 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $1.88 Million - $2.27 Million	42,954	42,954 $2.15 Million

Others Institutions Holding ESPR

# of Institutions

174

Shares Held

125M

Call Options Held

2.08M

Put Options Held

1.01M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $191M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account